Mycophenolate Mofetil Accord 250 mg capsules
Authorisation PA2315/064/001 · Accord Healthcare Ireland Ltd.
- Licence holder
- Accord Healthcare Ireland Ltd. (all products →)
- Active substance
- Mycophenolate mofetil
- Clinical trials
- 20 clinical trials →
- Dosage form
- Capsule, hard
- Route of administration
- Oral use
- ATC codes
- L04AA, L04AA06
- First authorised
- 16/12/2011
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Generic application (Article 10(1) of Directive No 2001/83/EC)
Mycophenolate mofetil: supply and approvals
17 authorised products on the HPRA list contain Mycophenolate mofetil. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 14 years (since 16 December 2011). The HPRA list marks it as marketed in Ireland.
Other medicines with Mycophenolate mofetil in Ireland
16 other products on the HPRA list contain Mycophenolate mofetil, from 6 licence holders; 3 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Mycolat 250 mg hard capsules | Rowex Limited, | National authorisation (PA) | Marketed |
| Mycolat 500 mg Film-coated tablets | Rowex Limited, | National authorisation (PA) | Marketed |
| Mycophenolate Mofetil 500 mg film-coated Tablets | Accord Healthcare Ireland Ltd. | National authorisation (PA) | Marketed |
| CellCept 1 g/5 ml Powder for oral suspension | Roche Registration GmbH | Centralised EU authorisation | Not stated |
| CellCept 250 mg Capsule, hard | Roche Registration GmbH | Centralised EU authorisation | Not stated |
| CellCept 250 mg Capsule, hard | Roche Registration GmbH | Centralised EU authorisation | Not stated |
| CellCept 250 mg hard capsules | Roche Registration GmbH | Centralised EU authorisation | Not stated |
| CellCept 500 mg Film-coated tablet | Roche Registration GmbH | Centralised EU authorisation | Not stated |
| CellCept 500 mg Film-coated tablet | Roche Registration GmbH | Centralised EU authorisation | Not stated |
| CellCept 500 mg Powder for concentrate for solution for infusion | Roche Registration GmbH | Centralised EU authorisation | Not stated |
| Myclausen 500 mg film-coated tablets | Herbert J. Passauer GmbH & Co. KG | Centralised EU authorisation | Not stated |
| Myclausen 500 mg film-coated tablets | Herbert J. Passauer GmbH & Co. KG | Centralised EU authorisation | Not stated |
Other substances in ATC group L04AA
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 32 other active substances share the group L04AA with this product:
Leflunomide (9) · Sirolimus (5) · Tacrolimus (4) · Belimumab (3) · Upadacitinib Hemihydrate (3) · Everolimus (2) · Filgotinib maleate (2) · Mycophenolic acid (2) · Baricitinib (2) · Abatacept (2) · Ponesimod (2) · OZANIMOD (2) · Teriflunomide (1) · Satralizumab (1) · Vilobelimab (1) · Anti-human t-lymphocyte immunoglobulin from rabbits (1) · Imlifidase (1) · Ofatumumab (1) · Alemtuzumab (1) · Ritlecitinib (1) · and 12 more
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Accord Healthcare Ireland Ltd. holds 238 products on the HPRA list, with 113 different active substances; 137 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.